如何保障疫苗安全:中国疫苗监管体系评估
疫苗接种是应对传染病和保障公共卫生最经济有效的措施,但疫苗安全担忧仍导致接种犹豫。中国针对长春长生疫苗事件于2019年通过《疫苗管理法》,建立覆盖疫苗全生命周期的监管体系,引入上市许可持有人制度并明确各方责任与异常反应补偿。该法强调利用现代技术建设国家疫苗电子追溯平台。
要点
- 中国《疫苗管理法》建立覆盖疫苗全生命周期的监管体系。
- 引入疫苗上市许可持有人制度并明确各方法律责任。
- 强调建设国家疫苗电子追溯平台,并需完善风险管理和政企合作。
核心结论
- 中国通过《疫苗管理法》建立覆盖全生命周期的疫苗监管体系以保障疫苗安全。
- 需进一步完善疫苗风险管理机制、促进政府与非政府合作并避免不当市场干预。
主要发现
- 2019年《疫苗管理法》是中国首部关于疫苗监管的综合性立法。
- 该法建立覆盖疫苗全生命周期的监管体系,引入上市许可持有人制度。
- 该法规定各方法律责任,并进一步明确预防接种异常反应补偿制度。
- 该法强调利用现代技术建设国家疫苗电子追溯平台。
临床怎么用
- 通过法律框架明确疫苗全生命周期监管责任与异常反应补偿。
- 利用国家疫苗电子追溯平台实现疫苗全程追溯。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccination is the most economic and effective measure to deal with infectious diseases and protect public health. Nowadays, due to the spread of COVID-19 and the ensuing pandemic, safe, effective vaccines are in urgent need. However, due to concerns about vaccine safety, there is still reluctance to vaccinate. In China, in response to the Changchun Changsheng Vaccine incident, the National People's Congress Standing Committee passed the Vaccine Administration Law in 2019, which marks China's first comprehensive piece of legislation on vaccine regulation. The law establishes a regulatory system covering the entire life cycle of vaccines, introduces the vaccine marketing authorization holder system, stipulates the legal responsibilities of all parties, and further clarifies the compensation system for any individuals who exhibit abnormal reactions to vaccination. In addition, it emphasizes the use of modern technology to build a national vaccine electronic platform for tracing. To balance vaccine efficacy and safety, it is necessary to further improve the vaccine risk management mechanism, promote cooperation between government and non-governmental actors, and avoid improper interventions in the vaccine market.
引用
- Feng J, Li Q. How to ensure vaccine safety: An evaluation of China's vaccine regulation system. Vaccine. 2021. PMID: 34373122. doi:10.1016/j.vaccine.2021.07.081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。